Shares of Guardant Health (NASDAQ: GH) increased nearly 12% last month, according to data provided by S&P Global market Intelligence. The liquid biopsy pioneer reported solid third-quarter 2019 operating results highlighted by revenue growth that continues to impress. In fact, the business increased full-year 2019 revenue guidance for the fourth consecutive quarter.
Importantly, the diagnostic company's revenue growth is resulting in shrinking operating losses each quarter despite soaring operating expenses. Guardant Health ended September with over $825 million in cash, suggesting it has more than enough financial wiggle room to sacrifice near-term profitability for faster growth. The growth stock is now up 100% since the beginning of the year.
Image source: Getty Images.